Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation

被引：0
|
作者：
O Benjamini
M Koren-Michowitz
N Amariglio
N Kroger
A Nagler
A Shimoni
机构：
[1] Chaim Sheba Medical Center,Division of Hematology and Bone Marrow Transplantation
来源：
Leukemia | 2008年 / 22卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1961 / 1963
页数：2
相关论文
共 50 条
  • [41] Development of paroxysmal nocturnal hemoglobinuria in a patient after mudallohsct due to JAK2V617F-positive myelofibrosis-a case of successful treatment with the second transplantation from another donor
    Tomaszewska, Agnieszka
    Nasilowska-Adamska, Barbara
    Solarska, Iwona
    Halaburda, Kazimierz
    BONE MARROW TRANSPLANTATION, 2019, 54 : 618 - 618
  • [42] JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse
    Lange, Thoralf
    Edelmann, Anja
    Siebolts, Udo
    Krahl, Rainer
    Nehring, Claudia
    Jakel, Nadja
    Cross, Michael
    Maier, Jacqueline
    Niederwieser, Dietger
    Wickenhauser, Claudia
    HAEMATOLOGICA, 2013, 98 (05) : 722 - 728
  • [43] Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation
    Yan, Chen-Hua
    Liu, Dai-Hong
    Liu, Kai-Yan
    Xu, Lan-Ping
    Liu, Yan-Rong
    Chen, Huan
    Han, Wei
    Wang, Yu
    Qin, Ya-Zhen
    Huang, Xiao-Jun
    BLOOD, 2012, 119 (14) : 3256 - 3262
  • [44] ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) FOR MYELOFIBROSIS RESULTED IN DISAPPEARANCE OF CONSTITUTIONAL SYMPTOMS, REDUCTION OF SPLEEN SIZE AND DECLINE OF THE JAK2V617F ALLELE RATIO
    Wieczorkiewicz, A.
    Helbig, G.
    Markiewicz, M.
    Kruzel, T.
    Wozniczka, K.
    Kyrcz-Krzemien, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 657 - 657
  • [45] Successful Treatment With Venetoclax Plus Azacytidine Combined With Radiation Therapy and Donor Lymphocyte Infusion in a Patient With Extramedullary Relapse of Acute Myeloid Leukemia After Stem Cell Transplantation
    Shirato, Shotaro
    Iyama, Satoshi
    Fujimi, Akihito
    Takahashi, Satoshi
    Kobune, Masayoshi
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (02)
  • [46] JAK2 V617F quantitation versus donor chimerism to monitor engraftment kinetics post-allogeneic haematopoietic stem cell transplantation for myeloproliferative neoplasms
    Haslam, K.
    Molloy, K. M.
    Conneally, E.
    Langabeer, S. E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 61 - 62
  • [47] Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case
    Penter, Livius
    Gohil, Satyen H.
    Huang, Teddy
    Thrash, Emily M.
    Schmidt, Dominik
    Li, Shuqiang
    Severgnini, Mariano
    Neuberg, Donna
    Hodi, F. Stephen
    Livak, Kenneth J.
    Zeiser, Robert
    Bachireddy, Pavan
    Wu, Catherine J.
    BLOOD ADVANCES, 2021, 5 (22) : 4701 - 4709
  • [48] Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by droplet-digital polymerase chain reaction
    Vivian W.K. Li
    Rita Yim
    Paul Lee
    Lynn Chin
    Lester Au
    Garret M.K. Leung
    Joycelyn Sim
    Albert K.W. Lie
    Eric Tse
    Yok-Lam Kwong
    Harinder Gill
    Annals of Hematology, 2023, 102 : 2517 - 2527
  • [49] Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by droplet-digital polymerase chain reaction
    Li, Vivian W. K.
    Yim, Rita
    Lee, Paul
    Chin, Lynn
    Au, Lester
    Leung, Garret M. K.
    Sim, Joycelyn
    Lie, Albert K. W.
    Tse, Eric
    Kwong, Yok-Lam
    Gill, Harinder
    ANNALS OF HEMATOLOGY, 2023, 102 (09) : 2517 - 2527
  • [50] Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation
    Steckel, Nina K.
    Koldehoff, Michael
    Ditschkowski, Markus
    Beelen, Dietrich W.
    Elmaagacli, Ahmet H.
    TRANSPLANTATION, 2007, 83 (11) : 1518 - 1520
12345